Proton pump inhibitors to control phosphorus levels in hemodialysis patients.
作者信息
Hojati Amineh
机构信息
Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
出版信息
Caspian J Intern Med. 2024 Oct 27;16(1):185-186. doi: 10.22088/cjim.16.1.185. eCollection 2025 Winter.
Abstract
摘要
相似文献
1
Proton pump inhibitors to control phosphorus levels in hemodialysis patients.
Caspian J Intern Med. 2024 Oct 27;16(1):185-186. doi: 10.22088/cjim.16.1.185. eCollection 2025 Winter.
2
Influence of proton pump inhibitors and histamine H receptor antagonists on serum phosphorus level control by calcium carbonate in patients undergoing hemodialysis: a retrospective medical chart review.
J Pharm Health Care Sci. 2016 Nov 22;2:34. doi: 10.1186/s40780-016-0068-1. eCollection 2016.
3
Proton pump inhibitors with calcium acetate on serum phosphorus levels in hemodialysis patients.
Caspian J Intern Med. 2023 Fall;14(4):737-740. doi: 10.22088/cjim.14.4.737.
4
Effect of famotidine and lansoprazole on serum phosphorus levels in hemodialysis patients on calcium carbonate therapy.
Clin Nephrol. 2007 Aug;68(2):93-8. doi: 10.5414/cnp68093.
5
Proton pump inhibitors use in hemodialysis patients and serum magnesium levels.
Int J Clin Exp Med. 2015 Nov 15;8(11):21689-93. eCollection 2015.
6
Proton Pump Inhibitors and Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Hemodialysis Patients: Results from the Japan Dialysis Outcomes and Practice Patterns Study.
Am J Nephrol. 2024;55(2):165-174. doi: 10.1159/000534701. Epub 2023 Nov 7.
7
High- versus low-dose proton pump inhibitors post endoscopic hemostasis in hemodialysis cases with peptic ulcer bleeding.
Acta Gastroenterol Belg. 2021 Jan-Mar;84(1):3-8. doi: 10.51821/84.1.654.
8
Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients.
Ren Fail. 2020 Nov;42(1):799-806. doi: 10.1080/0886022X.2020.1803085.
9
Proton pump inhibitors may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis.
Pharmacoepidemiol Drug Saf. 2022 Jun;31(6):670-679. doi: 10.1002/pds.5428. Epub 2022 Mar 24.
10
Severe Anemia from Multiple Gastric Hyperplastic Polyps in a Hemodialysis Patient after Long-term Use of a Proton-pump Inhibitor.
Intern Med. 2024;63(5):649-657. doi: 10.2169/internalmedicine.2091-23.
本文引用的文献
1
Proton pump inhibitors with calcium acetate on serum phosphorus levels in hemodialysis patients.
Caspian J Intern Med. 2023 Fall;14(4):737-740. doi: 10.22088/cjim.14.4.737.
2
'Phos'tering a Clear Message: The Evolution of Dietary Phosphorus Management in Chronic Kidney Disease.
J Ren Nutr. 2023 Nov;33(6S):S13-S20. doi: 10.1053/j.jrn.2023.05.004. Epub 2023 Jun 19.
3
Phosphate intake, hyperphosphatemia, and kidney function.
Pflugers Arch. 2022 Aug;474(8):935-947. doi: 10.1007/s00424-022-02691-x. Epub 2022 May 5.
4
Nutrition in Kidney Disease: Core Curriculum 2022.
Am J Kidney Dis. 2022 Mar;79(3):437-449. doi: 10.1053/j.ajkd.2021.05.024. Epub 2021 Dec 1.
Zotero 插件